Ang II enhances tubular cell Ets-1 expression and associated down stream signaling is mediated through AT1 receptors

Renal Failure

Volumn 32, Issue 8, 2010, Pages 986-991

  Kumar, Dileep ^a   Luan, Liming ^a   Pathak, Shresh ^a   Salhan, Divya ^a   Magoon, Sandeep ^a   Singhal, Pravin C ^a  

^a North Shore LIJ Health System ^*  (United States)

Author keywords

Angiotensin II; Ets 1; MCP 1; P21; PAI 1

Indexed keywords

A 9525; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P21; TELMISARTAN; TRANSCRIPTION FACTOR ETS 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; CELLULAR STRESS RESPONSE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; IN VITRO STUDY; INFLAMMATION; KIDNEY CORTEX; KIDNEY DISTAL TUBULE; KIDNEY TUBULE CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; CELL CULTURE TECHNIQUES; KIDNEY TUBULES, PROXIMAL; MALE; MICE; PROTO-ONCOGENE PROTEIN C-ETS-1; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; SIGNAL TRANSDUCTION; VASOCONSTRICTOR AGENTS;

EID: 77955939678     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2010.501936     Document Type: Article

References (33)

1. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med. 1988;318:1657-1666.
2. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116:288-296.
3. Fogo AB. Progression and potential regression of glomerulosclerosis. Kidney Int. 2001;59:804-819.
4. Michael AF, Keane WF, Raij L, Vernier RL, Mauer SM. The glomerular mesangium. Kidney Int. 1980;17:141-154.
5. Matsusaka T, Hymes J, Ichikawa I. Angiotensin in progressive renal diseases: Theory and practice. J Am Soc Nephrol. 1996;7:2025-2043.
6. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int. 1996;49:578-598.
7. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int. 2000;57:1803-1817.
8. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int. 2005;67:799-812.
9. Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression or renal disease: From hemodynamics to cell biology. Nephron Physiol. 2003;93:3-13.
10. Vaziri ND, Bai Y, Ni Z, et al. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J Pharmacol Exp Ther. 2007;323:85-93.
11. Manea A, Manea SA, Gafencu AV, Raicu M, Simionescu M. AP-1-dependent transcriptional regulation of NADPH oxidase in human aortic smooth muscle cells: Role of p22phox subunit. Arterioscler Thromb Vasc Biol. 2008;28:878-885.
12. Banes-Berceli AK, Shaw S, Ma G, et al. Effect of simvastatin on high glucose-and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol. 2006;291:F116-F121.
13. Giasson E, Servant MJ, Meloche S. Cyclic AMP-mediated inhibition of angiotensin II-induced protein synthesis is associated with suppression of tyrosine phosphorylation signaling in vascular smooth muscle cells. J Biol Chem. 1997;272:26879-26886.
14. Muller DN, Dechend R, Mervaala EM, et al. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000;35:193-201.
15. Theuer J, Dechend R, Muller DN, et al. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord. 2002;2:3.
16. Zhan Y, Brown C, Maynard E, et al. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest. 2005;115:2508-2516.
17. Wasylyk B, Hahn SL, Giovane A. The Ets family of transcription factors. Eur J Biochem. 1993;211:7-18.
18. Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer. 2003;2:29.
19. Garvie CW, Pufall MA, Graves BJ, Wolberger C. Structural analysis of the autoinhibition of Ets-1 and its role in protein partnerships. J Biol Chem. 2002;277:45529-45536.
20. Risau W, Flamme I. Vasculogenesis. Annu. Rev. Cell Dev Biol. 1995;11:73-91.
21. Oda N, Abe M, Sato Y. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. J Cell Physiol. 1999;178: 121-132.
22. Nakano T, Abe M, Tanaka K, et al. Angiogenesis inhibition by transdominant mutant Ets-1. J Cell Physiol. 2000;184: 255-262.
23. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: Roles of apoptosis, inflammation, and fibrosis [review]. Hypertension 2001;38:581-587.
24. Zhang C, Kavurma MM, Lai A, Khachigian, LM. Ets-1 protects vascular smooth muscle cells from undergoing apoptosis by activating p21WAF1/Cip1: ETS-1 regulates basal and inducible p21WAF1/Cip transcription via distinct cis-acting elements in the p21WAF/Cip1 promoter. J Biol Chem. 2003;278:27903-27909.
25. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999;99:3050-3055.
26. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 1997;51:164-172.
27. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol. 2002;283:F209-F220.
28. Ma LJ, Fogo AB. Angiotensin as inducer of plasminogen activator inhibitor-1 and fibrosis. Contrib Nephrol. 2001;135: 161-170.
29. Kaikita K, Fago AB, Ma L, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001;104:839-844.
30. Taal MW, Zandi-Nejad K, Weening B, et al. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int. 2000;58:1664-1676.
31. Ruiz-Ortega M, Bustos C, Hernández-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol. 1998;161:430.
32. Anders HJ, Belemezova E, Eis V, et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol. 2004;15:1504-1513.
33. Morrissey JJ, Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol. 1998;274:F580-F586.